Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer: A Strategic Move for PAS-004 Clinical Development

Key Highlights

• Appointment of Dr. Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (CMO) effective May 1, 2026.
• Dr. Krishnan to lead clinical development and medical strategy for PAS-004, a next-generation macrocyclic MEK inhibitor.
• PAS-004 is currently in Phase 1 clinical trials for advanced cancer and for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas.
• Dr. Krishnan brings over 20 years of clinical development experience, including key roles in the approval of cobimetinib (Cotellic™), an FDA-approved MEK inhibitor.

Detailed Report

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company, has announced the appointment of Dr. Kartik Krishnan, M.D., Ph.D., as its new Chief Medical Officer effective May 1, 2026. Dr. Krishnan will play a pivotal role in steering the company’s clinical development and medical strategy as it advances its lead drug candidate, PAS-004, through the clinic for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform and cutaneous neurofibromas.

According to Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea, “Dr. Krishnan’s strategic approach to clinical development and his proven track record in advancing novel therapies from early discovery through regulatory approval are highly relevant to our mission. His direct experience with the development and approval of cobimetinib, an FDA-approved MEK inhibitor, will benefit the progression of our PAS-004 program.”

Why This Matters to Shareholders

• Leadership Impact: Dr. Krishnan’s appointment signals a strengthening of Pasithea’s executive team with a leader who has previously driven FDA approvals and late-stage clinical successes. This could enhance investor confidence in the company’s clinical pipeline and regulatory prospects.
• PAS-004 Potential: The company emphasizes PAS-004’s differentiated pharmacokinetic (PK) profile, which may offer an optimal balance of safety, tolerability, and efficacy. Dr. Krishnan’s expertise with MEK inhibitors, especially cobimetinib, positions him to maximize the value and clinical progress of PAS-004.
• Pipeline Progress: PAS-004 is currently being evaluated in two ongoing Phase 1 clinical trials: one for advanced cancer and another for NF1-associated plexiform neurofibromas. The outcome of these trials and Dr. Krishnan’s leadership could significantly influence future regulatory milestones and market opportunity for the company.
• Broader Development Opportunities: Dr. Krishnan’s history includes expanding indications for MEK inhibitors beyond melanoma, such as in Langerhans cell histiocytosis and novel combinations in breast and colon cancer, suggesting the potential for PAS-004 to address additional rare and pediatric diseases.

Background on Dr. Kartik Krishnan

Dr. Krishnan brings more than 20 years of experience in clinical development, pharmacovigilance, regulatory affairs, and R&D strategy. His recent roles include:

• Chief Executive Officer at OncoNano Medicines, a developer of anti-cancer assets.
• Chief Medical Officer at Arcus Biosciences, focusing on immuno-oncology combination therapies.
• Clinical and medical director roles at Astex Pharmaceuticals, Genentech, Five Prime Therapeutics, BioMarin, and Amgen.
• Academic experience as a faculty member in the Department of Pediatrics at the University of Arizona.

Notably, during his tenure at Genentech, Dr. Krishnan played an integral role in the clinical team for cobimetinib (Cotellic™), contributing to its approval for use in combination with vemurafenib (Zelboraf™) for specific forms of melanoma in the United States and Europe. He also advanced monotherapy and combination strategies for MEK inhibitors in other indications, demonstrating a broad vision for these therapies.

About PAS-004 and Current Clinical Trials

PAS-004 is a next-generation macrocyclic MEK inhibitor designed for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The drug is currently being tested in:

• A Phase 1 clinical trial in patients with advanced cancer (NCT06299839).
• A Phase 1/1b clinical trial in patients with NF1-associated plexiform neurofibromas (NCT0696565), focusing on symptomatic and inoperable, incompletely resected, or recurrent tumors.

Shareholders should note that success in these clinical trials could represent significant value creation, while setbacks or failure to meet clinical endpoints could pose downside risks. The company cautions that forward-looking statements are subject to risks and uncertainties, including the potential for clinical results to differ from current observations or expectations.

Investor Considerations

• This leadership appointment could be price sensitive for KTTA shares, as it signals potential acceleration and de-risking of the company’s lead clinical program and pipeline expansion opportunities.
• Clinical trial results in advanced cancer and NF1 are upcoming catalysts that may materially affect share value depending on trial outcomes, regulatory feedback, and further development milestones.

Contact Information

For further information, investors can contact Patrick Gaynes, Investor Relations at [email protected].

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those anticipated. Investors should consult official Pasithea Therapeutics filings with the U.S. Securities and Exchange Commission and seek professional advice before making any investment decisions.

View Pasithea Therapeutics Corp. Historical chart here